Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Rumpl3StiltSkinon Apr 05, 2022 2:50pm
179 Views
Post# 34577778

RE:RE:RE:The 23 Optimized Patients

RE:RE:RE:The 23 Optimized Patientsand at 180 days this same group will all get a second optiized treatment. I'm guessing this number could be close to the final number of CR at 450 days.

We're talking about mostly an older and fragile patient population here. Could be a bunch of reasons why they aren't CR after 90 days... And I expect as we get more optimized patients treated this 90day CR % will improve a bit as well.

stocksnbonds458 wrote: For me, the only relevant data is the 23 optimized patients in phase two- these are the ONLY numbers I have been waiting for. After 90 days 52.2% of these 23 patients is CR according to TLT. This as an ABSOLUTELY ASTOUNDING number. For them to say encouraging instead of doing backflips and shouting from the building tops is because they are playing it low key for obvious reasons. This is game changing


<< Previous
Bullboard Posts
Next >>